Free Access
Med Sci (Paris)
Volume 21, Number 10, Octobre 2005
Page(s) 888 - 894
Section Recherche et partenariat
Published online 15 October 2005
  1. Moller HJ. Suicide, suicidality and suicide prevention in affective disorders. Acta Psychiatr Scand 2003; 418 (suppl) : 73–80. [Google Scholar]
  2. Vida S, Looper K. Precision and comparability of adverse event rates of newer antidepressants. J Clin Psychopharmacol 1999; 19 : 416–26. [Google Scholar]
  3. Montgomery SA, Kennedy SH, Burrows GD, et al. Absence of discontinuation symptoms with agomelatine and occurrence of discontinuation symptoms with paroxetine: a randomized, double-blind, placebo-controlled discontinuation study. Int Clin Psychopharmacol 2004; 19 : 271–80. [Google Scholar]
  4. Manji HK, Gottesman II, Gould TD. Signal transduction and genes-to-behaviors pathways in psychiatric diseases. Sci STKE 2003; 207 : pe49. [Google Scholar]
  5. Reus VI, Wolkowitz OM. Antiglucocorticoid drugs in the treatment of depression. Expert Opin Investig Drugs 2001; 10 : 1789–96. [Google Scholar]
  6. Griebel G, Simiand J, Steinberg R, et al. 4-(2-Chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3- fluoro-4- methylphenyl)ethyl]5-methyl-N-(2-propynyl)-1, 3- thiazol-2-amine hydrochloride (SSR125543A), a potent and selective corticotrophin-releasing factor(1) receptor antagonist. II. Characterization in rodent models of stress-related disorders. J Pharmacol Exp Ther 2002; 301 : 333–45. [Google Scholar]
  7. Kramer MS, Cutler N, Feighner J, et al. Distinct mechanism for antidepressant activity by blockade of central substance P receptors. Science 1998; 281 : 1640–5. [Google Scholar]
  8. Skolnick P. Antidepressants for the new millennium. Eur J Pharmacol 1999; 375 : 31–40. [Google Scholar]
  9. Kempermann G, Kronenberg G. Depressed new neurons. Adult hippocampal neurogenesis and a cellular plasticity hypothesis of major depression. Biol Psychiatry 2003; 54 : 499–503. [Google Scholar]
  10. Malberg JE, Schecter LE. Increasing hippocampal neurogenesis: a novel mechanism for antidepressant drugs. Curr Pharm Des 2005; 11 : 145–55. [Google Scholar]
  11. Henn FA, Vollmayr B. Neurogenesis and depression: etiology or epiphenomenon ? Biol Psychiatry 2004; 56 : 146–50. [Google Scholar]
  12. Brown R, Kocsis JH, Caroff S, et al. Differences in nocturnal melatonin secretion between melancholic depressed patients and control subjects. Am J Psychiatry 1985; 142 : 811–6. [Google Scholar]
  13. Souetre E, Salvati E, Belugou JL, et al. Circadian rhythms in depression and recovery: evidence for blunted amplitude as the main chronobiological abnormality. Psychiatr Res 1989; 28 : 263–8. [Google Scholar]
  14. Cheeta S, Ruigt G, Van Proosdij J, Willner P. Changes in sleep architecture following chronic mild stress. Biol Psychiatry 1997; 41 : 419–27. [Google Scholar]
  15. Gorka Z, Moryl E, Papp M. Effect of chronic mild stress on circadian rhythms in the locomotor activity in rats. Pharmacol Biochem Behav 1996; 54 : 229–34. [Google Scholar]
  16. Sekula LK, Lucke JF, Heist EK, et al. Neuroendocrine aspects of primary endogenous depression. XV. Mathematical modeling of nocturnal melatonin secretion in major depressives and normal controls. Psychiatr Res 1997; 69 : 143–53. [Google Scholar]
  17. Szymanska A, Rabe-Jablonska J, Karasek M. Diurnal profile of melatonin concentrations in patients with major depression: relationship to the clinical manifestation and antidepressant treatment. Neuroendocrinol Lett 2001; 22 : 192–8. [Google Scholar]
  18. Yous S, Andrieux J, Howell HE, et al. Novel naphthalenic ligands with high affinity for the melatonin receptor. J Med Chem 1992; 35 : 1484–6. [Google Scholar]
  19. Van Reeth O, Olivares E, Zhang Y, et al. Comparative effects of a melatonin agonist on the circadian system in mice and Syrian hamsters. Brain Res 1997; 762 : 185–94. [Google Scholar]
  20. Pitrosky B, Kirsch R, Malan A, et al. Organization of rat circadian rhythms during daily infusion of melatonin or S20098, a melatonin agonist. Am J Physiol Regul Integr Comp Physiol 1999; 277 : R812–28. [Google Scholar]
  21. Martinet L, Guardiola-Lemaitre B, Mocaer E. Entrainment of circadian rhythms by S-20098, a melatonin agonist, is dose and plasma concentration dependent. Pharmacol Biochem Behav 1996; 54 : 713–8. [Google Scholar]
  22. Armstrong SM, Mac-Nulty OM, Guardiola-Lemaitre B, Redman JR. Successful use of S20098 and melatonin in an animal model of delayed sleep-phase syndrome (DSPS). Pharmacol Biochem Behav 1993; 46 : 45–9. [Google Scholar]
  23. Redman JR, Guardiola-Lemaitre B, Brown M, et al. Dose dependent effects of S-20098, a melatonin agonist, on direction of re-entrainment of rat circadian activity rhythms. Psychopharmacology (Berl) 1995; 118 : 385–90. [Google Scholar]
  24. Van Reeth O, Weibel L, Olivares E, et al. Melatonin or a melatonin agonist corrects age-related changes in circadian response to environmental stimulus. Am J Physiol Regul Integr Comp Physiol 2001; 280 : R1582–91. [Google Scholar]
  25. Weibel L, Turek FW, Mocaer E, Van Reeth O. A melatonin agonist facilitates circadian resynchronization in old hamsters after abrupt shifts in the light-dark cycle. Brain Res 2000; 880 : 207–11. [Google Scholar]
  26. Van Reeth O, Olivares E, Turek FW, et al. Resynchronisation of a diurnal rodent circadian clock accelerated by a melatonin agonist. Neuroreport 1998; 9 : 1901–5. [Google Scholar]
  27. Kant GJ, Bauman RA, Pastel RH, et al. Effects of controllable versus uncontrollable stress on circadian temperature rhythms. Physiol Behav 1991; 49 : 625–30. [Google Scholar]
  28. Kopp C, Vogel E, Rettori MC, et al. The effects of melatonin on the behavioural disturbances induced by chronic mild stress in C3H/He mice. Behav Pharmacol 1999; 10 : 73–83. [Google Scholar]
  29. Papp M, Gruca P, Boyer PA, Mocaer E. Effect of agomelatine in the chronic mild stress model of depression in the rat. Neuropsychopharmacology 2003; 28 : 694–703. [Google Scholar]
  30. Bourin M, Mocaer E, Porsolt R. Antidepressant-like activity of S 20098 (agomelatine) in the forced swimming test in rodents: involvement of melatonin and serotonin receptors. J Psychiatr Neurosci 2004; 29 : 126–33. [Google Scholar]
  31. Bertaina-Anglade V, Mocaer E, Drieu-La-Rochelle C. Antidepressant-like action of agomelatine (S20098) in the learned helpesness test. Int J Neuropsychopharmacol 2002; 5 : 1. [Google Scholar]
  32. Norman TR, Irons J, Cranston I. Effect of the novel antidepressant agomelatine in the olfactory bulbectomised rat. Int J Neuropsychopharmacol 2004; 7 (suppl 1) : S461. [Google Scholar]
  33. Mitchell PJ, Redfern PH. Animal models of depressive illness: the importance of chronic drug treatment. Curr Pharm Des 2005; 11 : 203. [Google Scholar]
  34. Millan MJ, Gobert A, Lejeune F, et al. The novel melatonin agonist agomelatine (S20098) is an antagonist at 5-hydroxytryptamine(2C) receptors, blockade of which enhances the activity of frontocortical dopaminergic and adrenergic pathways. J Pharmacol Exp Ther 2003; 306 : 954–64. [Google Scholar]
  35. Millan MJ, Brocco M, Gobert A, Dekeyne A. Anxiolytic properties of agomelatine, an antidepressant with melatoninergic and serotonergic properties: role of 5-HT(2C) receptor blockade. Psychopharmacology 2005; 177 : 1–12. [Google Scholar]
  36. Hanoun N, Mocaer E, Boyer PA, et al. Differential effects of the novel antidepressant agomelatine (S20098) versus fluoxetine on 5-HT(1A) receptors in the rat brain. Neuropharmacology 2004; 47 : 515–26. [Google Scholar]
  37. Daszuta A, Banasr M, Hery M, Mocaer E. Agomelatine, a new antidepressant drug, increases cell proliferation in adult hippocampus. 33rd Annual Meeting of the Society for Neuroscience, November 8-13, 2003. New-Orleans : Society for Neuroscience, 2003 : 849–3. [Google Scholar]
  38. Morley-Fletcher S, Mairesse J, Mocaer E, et al. Chronic treatment with agomelatine increases hippocampal cell proliferation in prenatally stressed rats. 33rd Annual Meeting of the Society for Neuroscience, November 8-13, 2003. New-Orleans : Society for Neuroscience, 2003 : 506–20. [Google Scholar]
  39. Wiley JL, Dance ME, Balster RL. Preclinical evaluation of the reinforcing and discriminative stimulus effects of agomelatine (S-20098), a melatonin agonist. Psychopharmacology (Berl) 1998; 140 : 503–9. [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.